Correlation between human immunodeficiency virus type 1 RNA levels in the female genital tract and immune activation associated with ulceration of the cervix.
To address the hypothesis that local immune activation resulting from genital ulceration enhances human immunodeficiency virus type 1 (HIV-1) replication and shedding into the genital tract, paired plasma and cervicovaginal lavage (CVL) samples were obtained from 12 HIV-infected women before and after treatment of cervical intraepithelial lesions. Two weeks after treatment, inflammation and ulceration of the cervix were accompanied by major increases in mean concentrations of HIV-1 RNA (200-fold), tumor necrosis factor-alpha, interleukin 6, and soluble markers shed by activated lymphocytes and macrophages (sCD25 and sCD14, respectively) in CVL samples (P<.01 for each), but not plasma. Strong temporal and quantitative correlations were observed between concentrations of immunological markers and HIV-1 load in this compartment during a 10-week follow-up. Furthermore, in the presence of genital ulceration, HIV-1 in CVL samples was more readily captured by antibodies directed against virion-associated HLA-DR, a marker of host-cell activation, compared with virus in plasma. We suggest that local immune activation increases HIV-1 load in genital secretions, potentially increasing the risk of HIV-1 transmission.
Lawn
S D
SD
Tuberculosis and Mycobacteriology Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. sil3@cdc.gov
Subbarao
S
S
Wright
T C
TC
Evans-Strickfaden
T
T
Ellerbrock
T V
TV
Lennox
J L
JL
Butera
S T
ST
Hart
C E
CE
D000328:Adult; D005260:Female; D005836:Genitalia, Female / Q000821:virology*; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification*; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D015850:Interleukin-6 / Q000032:analysis; D018950:Lipopolysaccharide Receptors / Q000032:analysis; D012367:RNA, Viral / Q000032:analysis*; D015375:Receptors, Interleukin-2 / Q000032:analysis; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D014456:Ulcer / Q000276:immunology / Q000821:virology*; D002577:Uterine Cervical Diseases / Q000276:immunology / Q000821:virology*; D002578:Uterine Cervical Dysplasia / Q000628:therapy / Q000821:virology
D006684:HLA-DR Antigens; D015850:Interleukin-6; D018950:Lipopolysaccharide Receptors; D012367:RNA, Viral; D015375:Receptors, Interleukin-2; D014409:Tumor Necrosis Factor-alpha